Premium
TREATMENT OF CORONARY ARTERIOSCLEROTIC HEART DISEASE WITH CHONDROITIN SULFATE‐A: PRELIMINARY REPORT *
Author(s) -
Morrison Lester M.
Publication year - 1968
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.1968.tb02762.x
Subject(s) - medicine , myocardial infarction , arteriosclerotic heart disease , angina , dose , cardiology , unstable angina , heparin , coronary arteries , chondroitin sulfate , arteriosclerosis , artery , glycosaminoglycan , anatomy
A bstract The acid mucopolysaccharide, chondroitin sulfate‐A (CSA), which is active in preventing experimentally‐induced atherosclerosis in monkeys, rats and rabbits, also has anticoagulant properties in rabbits and in patients with angina pectoris from coronary arteriosclerotic heart disease. For an average period of one and a half years (range, one to two years), CSA was administered orally (tablet or powder) to 60 patients with clinically manifest coronary arteriosclerotic heart disease, in dosages ranging from 1.5 to 10.0 gm daily. No toxic effects were noted and the medication was well tolerated. These patients were matched with a comparable group of 60 control patients for age, sex, and clinical and laboratory findings. In the 60 control patients, 13 acute coronary incidents occurred; 7 were myocardial infarctions, of which 2 were fatal and 6 required hospital treatment in coronary‐care units for “acute coronary insufficiency” or “acute myocardial ischemia” or impending myocardial infarction. In the 60 CSA‐treated patients there was only 1 coronary incident—a fatal case of myocardial infarction. This preliminary report suggests that “feasibility” studies are warranted to determine the therapeutic effects of CSA for the prevention of coronary arteriosclerotic heart disease in statistically designed, triple‐blind investigations on a larger series of patients over longer periods of time.